Amicus Therapeutics Company Description
Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. The company's enzyme replacement therapies are designed to target defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease, whose symptoms include skin rashes, impaired sweating, and gastrointestinal, heart, and kidney problems that vary in severity. Amicus is also developing drugs to treat Gaucher disease, a disorder that can cause anemia and skeletal lesions, and Pompe disease, which causes muscle weakness and impairs breathing, mobility, and heart function.
View the Comprehensive Company Description for Amicus Therapeutics
The Company Description provides a historical perspective of Amicus Therapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Amicus Therapeutics's evolution in the marketplace.
